https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Predicting Nasal High-Flow Treatment Success in Newborn Infants with Respiratory Distress Cared for in Nontertiary Hospitals https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41976 Wed 08 Nov 2023 09:55:46 AEDT ]]> Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomes https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48408 Thu 16 Mar 2023 14:04:23 AEDT ]]> The Promise of Single-cell Technology in Providing New Insights into the Molecular Heterogeneity and Management of Acute Lymphoblastic Leukemia https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52222 Thu 05 Oct 2023 10:30:50 AEDT ]]> Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18868 3 and 101–200 cells/mm3 were statistically significantly less likely to have virological failure, compared to those with a baseline CD4 count lower than 50 cells/mm 3 (OR=0.61, 95% CI 0.23–0.89; and OR=0.43, 0.18–0.78, respectively). In contrast, patients with a history of injecting drug use were statistically significantly more likely to have viraemia than otherwise (OR=1.32, 1.16–1.67). The PPV of the WHO immunological criteria was 60.1% (57.1–69.3%). Conclusions: Routine viral load tests should be conducted early to detect virological failure and prevent unnecessary changes to second-line treatments. To improve treatment outcomes, timely ART initiation and adherence to treatment among those with history of injecting drug use should be promoted.]]> Sat 24 Mar 2018 08:03:14 AEDT ]]>